Guillermo Pardo-de-Santayana

Dr. Guillermo Pardo-de-Santayana

Neuropsychiatric Research Institute Dr Lopez Ibor. Madrid, Spain.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Schizophrenia Research
Verified
Journal Article
Closed access
GPGuillermo Pardo-de-Santayana
Guillermo Pardo-de-Santayana
JVJavier Vazquez-Bourgon
Javier Vazquez-Bourgon
MGMarcos Gómez-Revuelta
Marcos Gómez-Revuelta
RARosa Ayesa-Arriola
Rosa Ayesa-Arriola
VFVictor Ortiz-Garcia de la Foz
Victor Ortiz-Garcia de la Foz
JPJosé María Pelayo-Terán
José María Pelayo-Terán

1 February 2021 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
GPGuillermo Pardo-de-Santayana
Guillermo Pardo-de-Santayana
MJMaría Juncal-Ruiz
María Juncal-Ruiz
JVJavier Vázquez-Bourgon
Javier Vázquez-Bourgon
LRLaura Riesco-Dávila
Laura Riesco-Dávila
VFVictor Ortiz-Garcia de la Foz
Victor Ortiz-Garcia de la Foz
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro

1 June 2020 in Data in Brief
Verified
Journal Article
Open access
GPGuillermo Pardo-de-Santayana
Guillermo Pardo-de-Santayana
JVJavier Vazquez-Bourgon
Javier Vazquez-Bourgon
MGMarcos Gómez-Revuelta
Marcos Gómez-Revuelta
RARosa Ayesa-Arriola
Rosa Ayesa-Arriola
VFVictor Ortiz-Garcia de la Foz
Victor Ortiz-Garcia de la Foz
JPJosé María Pelayo-Terán
José María Pelayo-Terán
This article describes data related to the research study entitled "Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study." [1]. We present data concerning the clinical and sociodemographic characteristics of a sample of drug-naïve patients with a first episode of non-affective psychosis. The dataset was obtained from a 3-year longitudinal intervention program as part of an ongoing 10-year epidemiological study. The tables and figure shown present the data from the analysis between the active psychosis (presence of positive psychotic symptoms), among other sociodemographic and clinical predictor variables, recorded during the 3-year longitudinal intervention program and the evaluation of the functional outcome (social functioning and functional recovery) present at the 10-year mark. The data explores how those early parameters could influence long-term outcome.